Startup based in Switzerland, most recent round Series B, 1 tracked investor.
Based in Switzerland, Anaveon is a startup founded in 2020. Its most recent tracked round is Series B. Brouky records 1 investor associated with the company.
Anaveon is a clinical-stage biopharmaceutical company developing antibody and protein-based biologics to modulate the immune system for autoimmune diseases and oncology. Its lead programs include ANV200, a PD-1–targeting T‑cell depleting antibody for autoimmune indications, and ANV600, in Phase I/II for solid tumours.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.